Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Catheters recalled due to defect—FDA highlights risk of stroke or brain damage
The recall was put in place after a hydrophilic coating was discovered on the inside of the devices. According to the FDA, patients treated with the catheters could face a number of significant risks.
FDA clears TAVR guidewire built with BASILICA in mind
The Telltale system was designed to assist cardiologists when BASILICA is required prior to TAVR.
New technique could help when cardiologists repair 2 leaky heart valves at once
Performing M-TEER and T-TEER on the same patient using a single guide catheter appears to be both safe and effective. Researchers shared their experience with this approach in Circulation: Cardiovascular Interventions.
‘Strongest growth in over a decade’: Heart tech helps Medtronic beat earnings expectations
The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward.
Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in
Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

Cardiologist Foluso Fakorede, MD, explains the most common health disparities he sees preventing care in rural Mississippi. #PADadvocate #PAD #CLI #CLTI #Healthdisparities #HealthdisparitiesMS

Cardiologist details the many health disparities he encounters in rural Mississippi

Foluso Fakorede, MD, an interventional cardiologist with Cardiovascular Solutions of Central Mississippi, says these issues are typically overlooked in today's healthcare environment.

doctor patient discharge after heart surgery

Next-day discharge after TAVR with a self-expanding valve: 4 key takeaways

Researchers explored STS/ACR data from nearly 30,000 TAVR patients, presenting their findings in the Journal of the American Heart Association.

doctor's open hand waiting for a payment

‘Concerning’ data connect industry payments to cardiologists with medical device use

U.S. physicians often receive payments from medical device manufacturers and pharmaceutical companies. New research in JAMA found a connection between receiving such payments and using specific devices—should the industry be concerned?

Abbott's Espirit BTK Everolimus Eluting Resorbable Scaffold gained U.S. FDA approval in April 2024. It is based on the former Abbott Absorb coronary stent, but indicated for use in peripheral artery lesions below the knee (BTK).

FDA approves Abbott’s resorbable stent for BTK arteries

The bioresorbable stent, examined at length for the LIFE-BTK clinical trial, stays in place for up to three years before completely dissolving.

Society of Thoracic Surgeons launches new risk calculators for SAVR after TAVR, other key heart surgeries

STS risk calculators are known as a go-to resource for cardiologists, surgeons and any other healthcare providers who manage the care of heart patients.

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF

Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

Cardiology groups share key update: ABMS seeking feedback on proposed Board of Cardiovascular Medicine

Five of the largest U.S. medical societies focused on cardiovascular health are one step closer to seeing their paradigm-shifting proposal become a reality.

Interventional Cardiology

Catheters recalled due to defect—FDA highlights risk of stroke or brain damage

FDA clears TAVR guidewire built with BASILICA in mind

New technique could help when cardiologists repair 2 leaky heart valves at once

‘Strongest growth in over a decade’: Heart tech helps Medtronic beat earnings expectations

Did Boston Scientific pull the plug too early on TAVR devices? Cardiologists weigh in